家族性额颞叶痴呆临床与生物标志物变化的时间顺序
研究纳入796例C9orf72、GRN和MAPT突变携带者及412例非携带对照,构建多模态疾病进展模型。发现临床与生物标志物进展的时间顺序因基因型而异。在预防试验模拟中,脑萎缩和血浆神经丝轻链(NfL)是最佳终点,而临床指标是早期症状试验的潜在终点。
要点
- 临床与生物标志物变化的时间顺序因基因型而异。
- 预防试验模拟中,脑萎缩和血浆NfL是最佳终点。
- 临床指标是早期症状试验的潜在终点。
核心结论
- 家族性额颞叶痴呆预防试验可行,但可能需要全球招募。
- 疾病进展模型有助于规划临床试验,包括选择最佳终点和入组标准以最大化检测治疗效应的效能。
研究设计与样本
- 研究纳入796例携带者和412例非携带对照,构建了包含纵向临床和神经心理评分、区域脑体积和血浆神经丝轻链(NfL)的多模态模型。
主要发现
- 临床和生物标志物进展的时间顺序因基因型(C9orf72、GRN和MAPT)而异。
- 在基于模型患者选择的预防试验模拟中,脑萎缩和NfL是最佳终点,而临床指标是早期症状试验的潜在终点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Unlike familial Alzheimer's disease, we have been unable to accurately predict symptom onset in presymptomatic familial frontotemporal dementia (f-FTD) mutation carriers, which is a major hurdle to designing disease prevention trials. We developed multimodal models for f-FTD disease progression and estimated clinical trial sample sizes in C9orf72, GRN and MAPT mutation carriers. Models included longitudinal clinical and neuropsychological scores, regional brain volumes and plasma neurofilament light chain (NfL) in 796 carriers and 412 noncarrier controls. We found that the temporal ordering of clinical and biomarker progression differed by genotype. In prevention-trial simulations using model-based patient selection, atrophy and NfL were the best endpoints, whereas clinical measures were potential endpoints in early symptomatic trials. f-FTD prevention trials are feasible but will likely require global recruitment efforts. These disease progression models will facilitate the planning of f-FTD clinical trials, including the selection of optimal endpoints and enrollment criteria to maximize power to detect treatment effects.
引用
- Staffaroni AM, Quintana M, Wendelberger B, et al. Temporal order of clinical and biomarker changes in familial frontotemporal dementia. Nat Med. 2022. PMID: 36138153. doi:10.1038/s41591-022-01942-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。